Overall, the analysis suggests that BTKi-based therapy is highly effective for treating CLL and CNSL. The specific conditions that lead to higher efficacy include being under 65 years old, having TN-CLL, and receiving combination therapy with acalabrutinib and chemotherapy. For CNSL, both acalabrutinib and zanubrutinib monotherapy are highly effective, but zanubrutinib may be the preferred option for CLL treatment. These findings provide valuable insights for clinicians in selecting optimal treatment strategies for their patients with CLL or CNSL.
![/data # iw --debug dev wlan0 connect -w "lucky-5g" auth open key 0:1234567890
Usage: iw [options] dev connect [-w] [] [] [auth open|shared] [key 0:abcde d:1:6162636465] [mfp:req/opt/no]
Join the network with ...](https://linuxcpp.0voice.com/zb_users/upload/2023/05/202305162239148267954.png)
![驱动代码
void kalRxTaskletSchedule(struct GLUE_INFO *pr)
{
static unsigned int num = 0;
tasklet_hi_schedule(&pr->rRxTask[(num++)%NR_CPUS]);
// tasklet_hi_schedule(&pr->rRxTask);
DBGLOG(HAL, ERROR,](https://linuxcpp.0voice.com/zb_users/upload/2023/05/202305162226144313964.png)
